**Author details**

Dorota Kopacz\* and Piotr Maciejewicz Department of Ophthalmology, Medical University of Warsaw, Warsaw, Poland

\*Address all correspondence to: dr.dk@wp.pl

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**47**

*Sjögren's Syndrome as an Ocular Problem: Signs and Symptoms, Diagnosis, Treatment*

[9] Report of the definition and classification of the international dry eye workshop. The Ocular Surface.

[10] Gupta A, Sadeghi PB, Akpek EK. Occult thyroid eye disease in patients presenting with dry eye syndrome. American Journal of Ophthalmology. 2009;**147**:919-923

[11] Ken E, Demirag MD, Beyazyildz E. Presence of Sjögren's syndrome in dry eye patients. Rheumatology (Sunnyvale). 2014;**4**(2):137

[12] Akpek EK, Klimava A, Thorne JE, Martin D, et al. Evaluation of patients with dry eye for presence of underlying Sjögren syndrome. Cornea.

[13] Tzioufas AG, Kapsogeorgou EK, Moutsopoulos HM. Pathogenesis of Sjögren's syndrome; what we know and what we should learn. Journal of

[14] Akpek EK, Gottsch JD. Immune defense at the ocular surface. Eye.

[15] Barone F, Bombardieri M, Manzo A, Blades MC, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjogren's syndrome. Arthritis and Rheumatism.

[16] Darion C, Devauchelle V, Hutin P, Le Berre R, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren's syndrome. Arthritis and Rheumatism. 2007;**56**:1334-1344

[17] Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren's syndrome: Implications for disease management and therapy.

Autoimmunity. 2012;**39**:4-8

2009;**28**(5):493-497

2003;**17**:949-956

2005;**52**:1773-1784

2007;**5**:75-92

*DOI: http://dx.doi.org/10.5772/intechopen.83821*

[1] Utine CA, Akpek EK. What ophthalmologists should know about Sjögren's syndrome. European Ophthalmic Review. 2010;**4**:77-80

[2] Gonzales AJ, Lietman TM. Ocular involvement in Sjögren's syndrome: Advances in therapy. Current Treatment Options in Neurology. 2018;**4**:99-109

[3] Billings M, Dye BA, Iafolla T, Baer AN, Grisius M, Alevizos I. Significance and implications of patient-reported xerostomia in Sjögren's syndrome: Findings from the National Institutes of Health cohort. eBioMedicine.

[4] Both T, Dalm VASH, van Hagen M, van Daele PLA. Reviewing primary Sjögren's syndrome: Beyond the dryness—From pathophysiology to diagnosis and treatment. International

Journal of Medical Sciences.

[5] Asmussen K, Andersen V, Bendixen G, Schiodt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren'ssyndrome: Evaluation in retrospective long-term study. Journal of Internal Medicine. 1996;**239**:475-482

[6] Song IS, Lee S-M. Ocular

Hanyang Medical Reviews.

[7] Kassan SS, Thomas TL,

2016;**36**:161-167

1978;**89**:888-892

manifestation of Sjögren's syndrome.

Moutsopoulos HM, Hoover R, et al. Increased risk of lymphoma in sicca syndrome. Annals of Internal Medicine.

[8] Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients

with SS. Scandinavian Journal of Rheumatology. 1995;**24**:342-345

2017;**14**(3):191-200

**References**

2016;**12**:270-279

*Sjögren's Syndrome as an Ocular Problem: Signs and Symptoms, Diagnosis, Treatment DOI: http://dx.doi.org/10.5772/intechopen.83821*
